Bao R - Search Results

1

Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.

Cai X, Zhai HX, Wang J, Forrester J, Qu H, Yin L, Lai CJ, Bao R, Qian C. Cai X, et al. Among authors: bao r. J Med Chem. 2010 Mar 11;53(5):2000-9. doi: 10.1021/jm901453q. J Med Chem. 2010. PMID: 20143778

2

CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy.

Bao R, Lai CJ, Qu H, Wang D, Yin L, Zifcak B, Atoyan R, Wang J, Samson M, Forrester J, DellaRocca S, Xu GX, Tao X, Zhai HX, Cai X, Qian C. Bao R, et al. Clin Cancer Res. 2009 Jun 15;15(12):4046-57. doi: 10.1158/1078-0432.CCR-09-0152. Epub 2009 Jun 9. Clin Cancer Res. 2009. PMID: 19509149

3

Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer.

Bao R, Lai CJ, Wang DG, Qu H, Yin L, Zifcak B, Tao X, Wang J, Atoyan R, Samson M, Forrester J, Xu GX, DellaRocca S, Borek M, Zhai HX, Cai X, Qian C. Bao R, et al. Mol Cancer Ther. 2009 Dec;8(12):3296-306. doi: 10.1158/1535-7163.MCT-09-0538. Mol Cancer Ther. 2009. PMID: 19952121

4

CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity.

Lai CJ, Bao R, Tao X, Wang J, Atoyan R, Qu H, Wang DG, Yin L, Samson M, Forrester J, Zifcak B, Xu GX, DellaRocca S, Zhai HX, Cai X, Munger WE, Keegan M, Pepicelli CV, Qian C. Lai CJ, et al. Among authors: bao r. Cancer Res. 2010 May 1;70(9):3647-56. doi: 10.1158/0008-5472.CAN-09-3360. Epub 2010 Apr 13. Cancer Res. 2010. PMID: 20388807

5

Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.

Qian C, Lai CJ, Bao R, Wang DG, Wang J, Xu GX, Atoyan R, Qu H, Yin L, Samson M, Zifcak B, Ma AW, DellaRocca S, Borek M, Zhai HX, Cai X, Voi M. Qian C, et al. Among authors: bao r. Clin Cancer Res. 2012 Aug 1;18(15):4104-13. doi: 10.1158/1078-0432.CCR-12-0055. Epub 2012 Jun 12. Clin Cancer Res. 2012. PMID: 22693356

6

A Dual PI3K/HDAC Inhibitor Induces Immunogenic Ferroptosis to Potentiate Cancer Immune Checkpoint Therapy.

Fan F, Liu P, Bao R, Chen J, Zhou M, Mo Z, Ma Y, Liu H, Zhou Y, Cai X, Qian C, Liu X. Fan F, et al. Among authors: bao r. Cancer Res. 2021 Dec 15;81(24):6233-6245. doi: 10.1158/0008-5472.CAN-21-1547. Epub 2021 Oct 28. Cancer Res. 2021. PMID: 34711611

7

Novel compounds in the treatment of lung cancer: current and developing therapeutic agents.

Bao R, Chan P. Bao R, et al. J Exp Pharmacol. 2011 Mar 16;3:21-34. doi: 10.2147/JEP.S7804. eCollection 2011. J Exp Pharmacol. 2011. PMID: 27186107 Free PMC article. Review.

8

Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.

Selvakumaran M, Pisarcik DA, Bao R, Yeung AT, Hamilton TC. Selvakumaran M, et al. Among authors: bao r. Cancer Res. 2003 Mar 15;63(6):1311-6. Cancer Res. 2003. PMID: 12649192

9

Ovarian epithelial cell lineage-specific gene expression using the promoter of a retrovirus-like element.

Selvakumaran M, Bao R, Crijns AP, Connolly DC, Weinstein JK, Hamilton TC. Selvakumaran M, et al. Among authors: bao r. Cancer Res. 2001 Feb 15;61(4):1291-5. Cancer Res. 2001. PMID: 11245422

10

Activation of cancer-specific gene expression by the survivin promoter.

Bao R, Connolly DC, Murphy M, Green J, Weinstein JK, Pisarcik DA, Hamilton TC. Bao R, et al. J Natl Cancer Inst. 2002 Apr 3;94(7):522-8. doi: 10.1093/jnci/94.7.522. J Natl Cancer Inst. 2002. PMID: 11929953

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

819 results

Search Page

Filters